Risk factors
Emergent BioSolutions (EBS) risk factors
Item 1A of every Emergent BioSolutions Inc. 10-K on file, and what changed from one year to the next. Readings are automated and can be wrong; check the filing for the exact wording.
- FY2025 10-K risk factors56 risks4 new3 dropped13 reworded
Emergent faces ongoing asset impairment risks, increased competition for products like NARCAN Nasal Spray, and execution challenges from its multi-year strategic divestiture and turnaround plan.
Filed Feb 27, 2026 - FY2024 10-K risk factors55 risks
Heavy reliance on US government procurement contracts and funding for medical countermeasures dominates the risk profile.
Filed Mar 04, 2025